Literature DB >> 23653981

Observational study of the safety of a cluster schedule for subcutaneous immunotherapy in a pediatric population.

A Peñas1, M García-González, M J Cruz, L Valdesoiro, J D Boot, H Larramona, O Asensio, R Grau, J Costa, M Bosque.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23653981

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN： 1018-9068            Impact factor:   4.333


× No keyword cloud information.
  2 in total

1.  13-year overview of serious adverse drug reactions following subcutaneous specific immunotherapy with a chemically modified allergen preparation.

Authors:  Andreas Distler; Debbie Pappelendam
Journal:  Allergo J Int       Date:  2015-12-17

2.  A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy.

Authors:  R Mösges; E M Kasche; E Raskopf; J Singh; L Sohlich; A Astvatsatourov; K Shah-Hosseini; S Pirotton; L Haazen; S R Durham; T Legon; G Zadoyan; M H Shamji
Journal:  Allergy       Date:  2017-12-22       Impact factor: 13.146
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.